1. Home
  2. RZLT vs RLMD Comparison

RZLT vs RLMD Comparison

Compare RZLT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

SELL

Current Price

$4.00

Market Cap

352.1M

Sector

Health Care

ML Signal

SELL

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

SELL

Current Price

$3.03

Market Cap

348.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RZLT
RLMD
Founded
2010
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
352.1M
348.8M
IPO Year
2011
2012

Fundamental Metrics

Financial Performance
Metric
RZLT
RLMD
Price
$4.00
$3.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
4
Target Price
$10.40
★ $10.75
AVG Volume (30 Days)
1.5M
★ 1.7M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
23.47
★ 45.28
EPS
★ N/A
N/A
Revenue
N/A
★ $13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2,517.77
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$1.07
$3.07
52 Week High
$11.17
$8.00

Technical Indicators

Market Signals
Indicator
RZLT
RLMD
Relative Strength Index (RSI) 46.33 36.77
Support Level $3.58 N/A
Resistance Level $4.22 $3.55
Average True Range (ATR) 0.36 0.43
MACD -0.01 -0.04
Stochastic Oscillator 35.74 1.45

Price Performance

Historical Comparison
RZLT
RLMD

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: